💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Moxifloxacin

CHEMBL32 Phase 4 承認済み Small molecule
Half-Life
12 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
401.4 g/mol
LogP
0.6
Phase
4

This broad-spectrum antibiotic belongs to the fluoroquinolone class and is used to treat bacterial infections of the lungs, sinuses, skin, and abdomen. It works by preventing bacteria from replicating their DNA, effectively stopping the infection from spreading.

分子量

401.4350 g/mol

LogP

0.60

TPSA

82.10 Ų

リピンスキーの五則

適合

治療領域

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Endometriosis Cardiovascular Disease Age-Related Macular Degeneration Pain Management Non-Small Cell Lung Cancer Rheumatoid Arthritis Osteoporosis Asthma Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Epilepsy Migraine Schizophrenia Infectious Disease Systemic Lupus Erythematosus Obesity Lymphoma Type 2 Diabetes Hypertension Breast Cancer Gout Chronic Pain Malaria HIV/AIDS Hepatitis C Tuberculosis Heart Failure Atrial Fibrillation Prostate Cancer Colorectal Cancer Leukemia

薬物分類

J — J - Antiinfectives for Systemic Use

作用機序

Fourth-generation fluoroquinolone inhibiting DNA gyrase and topoisomerase IV with enhanced anaerobic activity.

Pharmacokinetics (PK)

Half-Life 12 hours

Pharmacodynamics (PD)

機序

Fourth-generation fluoroquinolone inhibiting DNA gyrase and topoisomerase IV with enhanced anaerobic activity.

2D構造

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12

                

                

                
                

                    
InChI

                    
InChI=1S/C21H24FN3O4/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28)/t11-,16+/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C21H24FN3O4

                    

                    
                    

                        
HBD / HBA

                        
2 / 8

                    

                    
                    

                        
回転可能結合数

                        
4

                    

                    
                    
                    

                        
重原子数

                        
29

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
よくある質問

                

                    
                    

                        
                        

                            
This broad-spectrum antibiotic belongs to the fluoroquinolone class and is used to treat bacterial infections of the lungs, sinuses, skin, and abdomen. It works by preventing bacteria from replicating their DNA, effectively stopping the infection from spreading.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Fourth-generation fluoroquinolone inhibiting DNA gyrase and topoisomerase IV with enhanced anaerobic activity.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Moxifloxacin: Half-life: 12 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Moxifloxacin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Amoxicillin
                            Small molecule
                        
                        
                        
                            Azithromycin
                            Small molecule
                        
                        
                        
                            Ciprofloxacin
                            Small molecule
                        
                        
                        
                            Doxycycline
                            Small molecule
                        
                        
                    

                

                

                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL32.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 152946.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
医学的免責事項

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.